ArticleScientific reports2025

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

Sofia Aakko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.